ライフサイエンスコーパス: thrombolysis

1 lications for the assessment and delivery of thrombolysis.

2 ution of thrombosis during catheter-directed thrombolysis.

3 on HT subtypes and outcome after intravenous thrombolysis.

4 mes in patients with mild stroke who receive thrombolysis.

5 tibility-weighted imaging before intravenous thrombolysis.

6 pannus and thrombus, the latter amenable to thrombolysis.

7 on making were both associated with desiring thrombolysis.

8 itive, and 2731 (38.5%) received intravenous thrombolysis.

9 reater benefit when treated with intravenous thrombolysis.

10 dimer, indicative of ongoing coagulation and thrombolysis.

11 often have a decline in blood pressure after thrombolysis.

12 mplications or do not respond to intravenous thrombolysis.

13 y (bond overstretching) during flow-mediated thrombolysis.

14 r of eligible patients receiving intravenous thrombolysis.

15 ation and increasing rates of catheter-based thrombolysis.

16 both parameters, which peaked 1-3 days after thrombolysis.

17 hemorrhagic transformation following stroke thrombolysis.

18 o randomisation, stroke-related factors, and thrombolysis.

19 e ischemic stroke who receive intra-arterial thrombolysis.

20 cological target of human ischemic stroke is thrombolysis.

21 eatment by mechanical thrombectomy and/or IA thrombolysis.

22 e onset within 4.5 hours, the time window of thrombolysis.

23 nts with an ischemic stroke are eligible for thrombolysis.

24 0.86 (0.81 to 0.91) and 0.85 (0.81 to 0.90); thrombolysis 0.85 (0.75 to 0.97) and 0.85 (0.75 to 0.97)

25 OR] = 0.21; 95% CI, 0.18-0.24), lower use of thrombolysis (12% vs 19% of those with ischemic stroke;

26 1 minutes]) and from the door to intravenous thrombolysis (32 minutes [IQR, 24-47 minutes]) were sign

27 vasive intervention (22 patients angioplasty/thrombolysis, 62 TIPS, and 20 OLT) and 36 (22.9%) died.

28 Rates of golden hour thrombolysis, 7- and 90-day mortality, secondary intrace

29 ng adjusted OR: 0.61; 95% CI: 0.60 to 0.62) (thrombolysis adjusted OR: 0.80; 95% CI: 0.78 to 0.82).

30 Thrombolysis administration in Tyrol increased after pro

31 r comprehensive stroke management programme, thrombolysis administration increased and clinical outco

32 an states without similar stroke programmes, thrombolysis administration remained stable or declined

33 , admission to stroke unit (day 0 or 1), and thrombolysis administration.

34 e patients would be treated with intravenous thrombolysis and 20 more with endovascular stroke therap

35 9), the reperfusion rate was 75.6% (34.4% by thrombolysis and 65.6% by primary percutaneous coronary

36 VLCBV predicts PH after stroke thrombolysis and appears to be a more powerful predictor

37 istently report a reduction in delays before thrombolysis and cause-based triage in regard to the app

38 anticoagulation, while interventions such as thrombolysis and inferior vena cava filters are reserved

39 chemic stroke but, to date, only intravenous thrombolysis and intra-arterial measures to restore perf

40 d to identify studies addressing the role of thrombolysis and mechanical thrombectomy in acute stroke

41 formed in 144 and 146 patients randomized to thrombolysis and placebo, respectively) did not reveal s

42 evels, and the development and timely use of thrombolysis and stents in acute coronary syndrome to li

43 nhibits tissue plasminogen activator-induced thrombolysis and subsequent reduction of ischemic brain

44 literature, we propose new ways to approach thrombolysis and suggest potential prophylactic and ther

45 vated glycoprotein IIb/IIIa allows effective thrombolysis and the potential novel use as a fibrinolyt

46 o block tissue plasminogen activator-induced thrombolysis and to obtain neuroprotection and inhibitio

47 ecanalization of the occluded artery through thrombolysis and/or endovascular thrombectomy is restric

48 n off-hours pattern (door-to-needle time for thrombolysis), and a flow pattern whereby quality change

49 d, of whom 157 were eligible for intravenous thrombolysis, and 104 patients were enrolled.

50 te, secondary intracerebral hemorrhage after thrombolysis, and 7-day mortality.

51 mboembolism at baseline conditions and after thrombolysis, and in healthy controls.

52 amples were obtained prior to treatment with thrombolysis, and leukocyte RNA was assessed by microarr

53 Previous ICrH, thrombolysis, and male sex affected the risk, whereas an

54 reased the risk of PH 24 h after intravenous thrombolysis, and predicted poor clinical outcome indepe

55 efit of tissue plasminogen activator-induced thrombolysis; and 2) could be an efficient neuroprotecti

56 Thrombolysis appears safe and short-term outcomes are fa

57 ng-term follow-up, 65 deaths occurred in the thrombolysis arm and 53 occurred in the placebo arm.

58 sessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placeb

59 including time to neuroimaging and rates of thrombolysis, as well as outcomes, including death and d

60 ian NIHSS of 6.5 (range, 2-24), and received thrombolysis at a mean time of 10.3 +/- 2.6 LSN and 2.6

61 ase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST), we aimed to assess the efficacy a

62 ients with stroke cannot receive intravenous thrombolysis because the time of symptom onset is unknow

63 patients (71%) were treated with intravenous thrombolysis before IA therapy.

64 ur patterns of variation: a diurnal pattern (thrombolysis, brain scan within 12 h, brain scan within

65 n can be achieved mainly through intravenous thrombolysis, but other methods such as intra-arterial t

66 tion tube is more advantageous for efficient thrombolysis by enhancing cavitation-induced microstream

67 ation of NIHSS is higher in patients who are thrombolysis candidates.

68 ) or anticoagulation plus pharmacomechanical thrombolysis (catheter-mediated or device-mediated intra

69 The use of catheter-directed thrombolysis (CDT) in the treatment of acute proximal lo

70 ctice patterns and role of catheter-directed thrombolysis (CDT) in the treatment of inferior vena cav

71 5 (7.4%) experienced a symptomatic ICH after thrombolysis, compared to 29/655 (4.4%) patients without

72 -needle (DTN) times </=60 minutes for stroke thrombolysis, critical DTN process failures persist.

73 d that physicians should not presume to make thrombolysis decisions for incapacitated patients with a

74 us medical management, including intravenous thrombolysis, demonstrated strong positive data in suppo

75 y patients from being treated by intravenous thrombolysis due to the associated risks.

76 Compared with thrombolysis during control weeks, there was a reduction

77 s in rates of teleconsultations, intravenous thrombolysis, endovascular stroke therapies, and spoke-t

78 Golden hour thrombolysis entails no risk to the patients' safety and

79 he risk of ICH might outweigh the benefit of thrombolysis, especially in patients with multiple lobar

80 gh an evidence-based approach to intravenous thrombolysis for acute ischaemic stroke is pivotal, it i

81 The slow progress in thrombolysis for acute stroke has been multifactorial.

82 tween this index and response to intravenous thrombolysis for AIS has not been properly evaluated.

83 lly invasive catheter evacuation followed by thrombolysis for clot removal is safe and can achieve a

84 cant increased risk of symptomatic ICH after thrombolysis for ischaemic stroke in patients with CMBs.

85 Intravenous thrombolysis for ischaemic stroke remains underused worl

86 arise the value of immediate out-of-hospital thrombolysis for STEMI, and reconsider the potential the

87 ter experience with using pharmacomechanical thrombolysis for the treatment of thrombosed native arte

88 nd 96% in the conventional catheter-directed thrombolysis group (P = 0.33), and there was no differen

89 /- 27% in the conventional catheter-directed thrombolysis group (P = 0.91).

90 otic syndrome (47% in the pharmacomechanical-thrombolysis group and 48% in the control group; risk ra

91 in the ultrasound-assisted catheter-directed thrombolysis group and 54% +/- 27% in the conventional c

92 low-up period (12% in the pharmacomechanical-thrombolysis group and 8% in the control group, P=0.09).

93 in the ultrasound-assisted catheter-directed thrombolysis group and 96% in the conventional catheter-

94 yndrome were lower in the pharmacomechanical-thrombolysis group than in the control group at 6, 12, 1

95 in 18% of patients in the pharmacomechanical-thrombolysis group versus 24% of those in the control gr

96 HT regions after intra-arterial thrombolysis had lower permeability values on K(trans) m

97 treatment, patients who received golden hour thrombolysis had no higher risks for 7- or 90-day mortal

98 Although the field of acute thrombolysis has been making progress slowly for many ye

99 Pharmacomechanical catheter-directed thrombolysis (hereafter "pharmacomechanical thrombolysis

100 mage is the major risk factor for fatal post-thrombolysis ICH, but rapidly assessing BBB damage befor

101 otential to receive benefit from intravenous thrombolysis if they have favourable predictors of outco

102 ents with acute pulmonary embolism, systemic thrombolysis improves right ventricular (RV) dilatation,

103 ut maneuver in 9 cases (success rate, 100%), thrombolysis in 9 patients (success rate, 56%), and pump

104 e indicator for efficient use of intravenous thrombolysis in acute ischemic stroke (AIS).

105 The effectiveness of intravenous thrombolysis in acute ischemic stroke is time dependent.

106 specially in light of the severe underuse of thrombolysis in acute ischemic stroke.

107 ecommendations to treat ischemic stroke with thrombolysis in appropriate emergency circumstances unde

108 while reperfusion was assessed by using the Thrombolysis in Cerebral Infarction (TICI) scale.

109 with achievement of substantial reperfusion (Thrombolysis in Cerebral Infarction [TICI] 2b-3).

110 Recanalization (defined as Thrombolysis in Cerebral Infarction [TICI] score 2b-3) a

111 achieved angiographic reperfusion (score on Thrombolysis in Cerebral Infarction scale of grade 2-3)

112 sful revascularization defined as a modified Thrombolysis in Cerebral Infarction score of 2b or 3 at

113 ion was defined as a score of 2b or 3 on the Thrombolysis in Cerebral Infarction score.

114 Reperfusion was assessed with angiographic Thrombolysis in Cerebral Infarction scores at the end of

115 ilar in terms of substantial recanalization (Thrombolysis in Cerebral Ischemia scores 2B to 3; drip a

116 The safety of intravenous thrombolysis in ischemic stroke (IS) patients with chron

117 In a 66-patient subgroup with thrombolysis in myocardial infarction </=1 flow, there w

118 utcome was the incidence of no-/slow-reflow (Thrombolysis In Myocardial Infarction </=2).

119 ranch block identified patients with reduced Thrombolysis in Myocardial Infarction (0-2) flow with 70

120 d in Patients with Diabetes Mellitus (SAVOR)-Thrombolysis in Myocardial Infarction (TIMI) 53 is a ran

121 Successful recanalization means thrombolysis in myocardial infarction (TIMI) = 2 to 3.

122 The primary endpoint was thrombolysis in myocardial infarction (TIMI) clinically

123 nt elevation MI within 6 h of symptom onset, Thrombolysis In Myocardial Infarction (TIMI) flow grade

124 nset of symptoms within 12 hours, STEMI, and thrombolysis in myocardial infarction (TIMI) grade 0-1 f

125 The primary endpoint was a composite of Thrombolysis In Myocardial Infarction (TIMI) major and m

126 (MI), definite stent thrombosis, stroke, or Thrombolysis In Myocardial Infarction (TIMI) major bleed

127 ease in all non-coronary artery bypass graft Thrombolysis In Myocardial Infarction (TIMI) major bleed

128 ular death/myocardial infarction/stroke) and Thrombolysis in Myocardial Infarction (TIMI) major bleed

129 The rate of the key safety end point of all Thrombolysis in Myocardial Infarction (TIMI) major bleed

130 Recurrent PLATO major or Thrombolysis in Myocardial Infarction (TIMI) major non-c

131 ram, Age, Risk Factors, Troponin (HEART) and Thrombolysis in Myocardial Infarction (TIMI) risk scores

132 thway integrating 0- and 2-h hs-TnI results, Thrombolysis In Myocardial Infarction (TIMI) risk scores

133 immediate stenting (n=73) or DS (n=67) after Thrombolysis In Myocardial Infarction 3 flow restoration

134 in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36) trial and foll

135 ptimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38

136 ptimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction 38) study prasugre

137 ptimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study.

138 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) trial compared

139 or Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial in patie

140 or Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48) trial, compari

141 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48), the factor Xa

142 evention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction 50 (TRA 2 degrees

143 and Stroke in Patients With Atherosclerosis-Thrombolysis in Myocardial Infarction 50 (TRA2 degrees P

144 and Stroke in Patients With Atherosclerosis-Thrombolysis In Myocardial Infarction 50) was a multinat

145 Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51) trial, which d

146 apy in Subjects With Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51) trial.

147 Recorded in Patients With Diabetes Mellitus-Thrombolysis in Myocardial Infarction 53]), alogliptin (

148 mpared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54) (ticagrelor) w

149 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) randomized 21,

150 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial studied

151 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial, which r

152 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54), in which 21,1

153 Clopidogrel by Involving a Genetic Strategy-Thrombolysis In Myocardial Infarction 56) investigators

154 body Inhibition Combined With Statin thErapy-Thrombolysis In Myocardial Infarction 57) trial at high

155 patients (58.7% female, age 59 +/- 13, 78.6% thrombolysis in myocardial infarction [TIMI] </=2), 9% h

156 ajor bleeding or minor bleeding according to Thrombolysis in Myocardial Infarction [TIMI] criteria or

157 to Open Occluded Coronary Arteries [GUSTO], Thrombolysis in Myocardial Infarction [TIMI], and Acute

158 RS-PR showed higher discriminatory power for thrombolysis in myocardial infarction bleeding than BRS

159 criminatory power of BRS-PR (AUC = 0.809 for thrombolysis in myocardial infarction bleeding; AUC = 0.

160 1.31; 95% CI: 1.16 to 1.48; p < 0.0001) and Thrombolysis In Myocardial Infarction blush grade (TBG)

161 Thrombolysis In Myocardial Infarction coronary flow grad

162 In a subgroup of patients with thrombolysis in myocardial infarction flow </=1, nitrite

163 eft ventricular ejection fraction, and final thrombolysis in myocardial infarction flow <3.

164 Reduced Thrombolysis in Myocardial Infarction flow (0-2) was fou

165 arction thrombus grade; (2) postintervention thrombolysis in myocardial infarction flow and myocardia

166 NR was defined as thrombolysis in myocardial infarction flow grade </=2 an

167 ine at admission >132.6 mumol/l (1.5 mg/dl), Thrombolysis In Myocardial Infarction flow grade <3 afte

168 arameters such as blush grade (p = 0.63) and Thrombolysis In Myocardial Infarction flow grade (p = 0.

169 the proportion of patients who did not have Thrombolysis in Myocardial Infarction flow grade 3 in th

170 tion, is regularly lysing fibrin and induced Thrombolysis In Myocardial Infarction flow grade 3 paten

171 ameters including myocardial blush grade and Thrombolysis In Myocardial Infarction flow grade.

172 rhythms (24%), 32% had significantly reduced Thrombolysis in Myocardial Infarction flow.

173 equently used in patients with worse initial thrombolysis in myocardial infarction flow.

174 romboxane B2, reperfusion indexes (corrected Thrombolysis In Myocardial Infarction frame count and my

175 istically significant reduction in corrected Thrombolysis In Myocardial Infarction frame count more e

176 with pre-percutaneous coronary intervention Thrombolysis in Myocardial Infarction grade 0 to 1 flow,

177 Coronary flow remained within thrombolysis in myocardial infarction III definitions in

178 ded non-coronary artery bypass graft-related Thrombolysis In Myocardial Infarction major and minor bl

179 ncreased non-coronary artery bypass grafting Thrombolysis In Myocardial Infarction major bleeding (2.

180 The CABG-related Thrombolysis In Myocardial Infarction major bleeding was

181 tal composite bleeding-access site bleeding, thrombolysis in myocardial infarction major/minor bleedi

182 or Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction Study 48) with a f

183 Secondary end points are (1) residual thrombolysis in myocardial infarction thrombus grade; (2

184 evention of Atherothrombotic Ischemic Events-Thrombolysis in Myocardial Infarction) (vorapaxar) and P

185 mpared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction) 54 trial randomiz

186 e against 2 validated bleeding scales: TIMI (Thrombolysis In Myocardial Infarction) and GUSTO (Global

187 Symptom-to-reperfusion time, TIMI (Thrombolysis in Myocardial Infarction) blush grade, and

188 tom-to-first device time, and baseline TIMI (Thrombolysis In Myocardial Infarction) flow 0/1 versus 2

189 e) and the primary safety endpoint was TIMI (Thrombolysis In Myocardial Infarction) major bleeding.

190 The TIMI (Thrombolysis In Myocardial Infarction) Risk Score for Se

191 When stratified by the TIMI (Thrombolysis in Myocardial Infarction) Risk Score for Se

192 gnificant predictor in addition to the TIMI (Thrombolysis In Myocardial Infarction) risk score.

193 leeding defined according to the BARC, TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Ut

194 days after PCI were defined according to the thrombolysis in myocardial infarction, Randomized Evalua

195 apy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51), rivaroxaban r

196 he subgroup with high thrombus burden (TIMI [Thrombolysis in Myocardial Infarction] thrombus grade >/

197 rtery occlusion as an adjunct to intravenous thrombolysis in patients with acute stroke.

198 is helpful in identifying masses amenable to thrombolysis in patients with prosthetic valve dysfuncti

199 h accuracy and may guide the decision to use thrombolysis in patients with unknown time of stroke ons

200 V tPA enrolled in the Safe Implementation of Thrombolysis in Stroke (SITS) International Stroke Throm

201 Stroke Study II, and Safe Implementation of Thrombolysis in Stroke criteria.

202 rrhage within 7 days; Safe Implementation of Thrombolysis in Stroke Monitoring Study's (SITS-MOST) ha

203 the definition by the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST), whi

204 l complications associated with tPA-mediated thrombolysis in stroke.

205 Differences in use of thrombolysis in the nine counties of Tyrol in 2010 (rang

206 t include a vascular neurologist can provide thrombolysis in the prehospital setting faster than trea

207 able for molecular imaging of thrombosis and thrombolysis in vivo and represents a promising candidat

208 red with usual care alone (i.e., intravenous thrombolysis) in the management of acute ischemic stroke

209 nts with acute ischaemic stroke treated with thrombolysis, in relation to the presence of pre-treatme

210 to 44 min (29-60) in 2013; symptomatic post-thrombolysis intracerebral haemorrhages occurred in 28 o

211 mic stroke because the risks and benefits of thrombolysis involve deeply personal values.

212 Systemic thrombolysis is a consideration, but its risks of major

213 Pharmacomechanical thrombolysis is a minimally invasive, effective, durable

214 Thrombolysis is best reserved for severe VTE; inferior v

215 Time to thrombolysis is crucial for outcome in acute ischemic st

216 Intravenous thrombolysis is the mainstay of acute ischemic stroke ma

217 trolled clinical trial comparing intravenous thrombolysis (IVT) alone with IVT and adjunctive intra-a

218 Intravenous thrombolysis (IVT) followed by mechanical thrombectomy (

219 Intravenous thrombolysis (IVT) for acute ischemic stroke is subject

220 enchymal hematoma (PH) following intravenous thrombolysis (IVT) in ischemic stroke can occur either w

221 However, it is not known whether intravenous thrombolysis (IVT) is of added benefit in patients under

222 chemic stroke (AIS) treated with intravenous thrombolysis (IVT).

223 Pharmacomechanical thrombolysis led to more major bleeding events within 10

224 ntrol for the confounding variables of prior thrombolysis, location of occlusion, and operator expert

225 Of the 29 patients receiving thrombolysis (median National Institutes of Health Strok

226 from stroke recognition to administration of thrombolysis (median, 2.0 vs 1.2 hours; P < .001).

227 eceive ultrasound-assisted catheter-directed thrombolysis (N = 24) or conventional catheter-directed

228 s (N = 24) or conventional catheter-directed thrombolysis (N = 24).

229 Intra-pump obstruction was treated by thrombolysis (n = 9; success rate, 33%), pump exchange (

230 hrombus fragmentation (n=4), pharmacological thrombolysis (n=3) and stent placement (n=8).

231 At 24 hours after thrombolysis, neurologic improvement with concurrent dec

232 Older adults regard thrombolysis no less favorably when considering a situat

233 r and molecular mechanisms of thrombosis and thrombolysis of stroke are required.

234 enting as shock or arrest, emergent systemic thrombolysis or embolectomy is reasonable, while for low

235 ergency medical services, offers support for thrombolysis or immediate transfer for primary percutane

236 is, but other methods such as intra-arterial thrombolysis or mechanical thrombectomy can also be empl

237 artery occlusion" OR "retinal ischemia" AND "thrombolysis" OR "fibrinolysis" OR "tissue plasminogen a

238 te ischemic stroke and could be treated with thrombolysis, or had suffered a sudden cardiac arrest an

239 emic core threshold to predict infarction as thrombolysis patients with complete reperfusion.

240 r-directed fibrinolysis, ultrasound-assisted thrombolysis, percutaneous mechanical thrombus fragmenta

241 ns of VLCBV is strongly associated with post-thrombolysis PH.

242 Thrombolysis, previous ICrH, atrial fibrillation, and ma

243 lusion, with 59% having received intravenous thrombolysis prior to EVT.

244 thrombolysis (hereafter "pharmacomechanical thrombolysis") rapidly removes thrombus and is hypothesi

245 Our technology demonstrates a thrombolysis rate of 0.7 +/- 0.15 percent mass loss/min

246 Secondary outcomes included thrombolysis rate, secondary intracerebral hemorrhage af

247 Thrombolysis rates in ischemic stroke were 200 of 614 pa

248 Thrombolysis rates in ischemic stroke were 29% (310/1070

249 Thrombolysis regimen (20 mg r-tPA over 15 hours) was ide

250 hrombosis treated with a fixed-dose catheter thrombolysis regimen, the addition of intravascular ultr

251 olysis in Stroke (SITS) International Stroke Thrombolysis Register.

252 Thrombolysis-related haemorrhagic transformation (HT) su

253 ematoma expansion and improve the outcome of thrombolysis-related hemorrhage.

254 ost feared complications of the treatment is thrombolysis-related symptomatic intracerebral hemorrhag

255 Intravenous thrombolysis remains the mainstay treatment for acute is

256 , and long-term functional outcome in stroke thrombolysis remains unclear.

257 with usual care, the use of ambulance-based thrombolysis resulted in decreased time to treatment wit

258 based patient stratification for intravenous thrombolysis, revolutionized by the landmark National In

259 Thrombolysis should be considered for patients at low ri

260 randomized controlled trials of intravenous thrombolysis shows no statistically significant benefit

261 djustment for age, stroke severity, sex, and thrombolysis status showed that the distributions of 3-m

262 -1.10, adjusted for baseline NIHSS score and thrombolysis stratum).

263 (Pulmonary Embolism Thrombolysis study [PEITHO]; NCT00639743).

264 t up-to-date literature on imaging, systemic thrombolysis, surgical embolectomy, and catheter-directe

265 Among all patients who received thrombolysis, the proportion of golden hour thrombolysis

266 Primary outcome was alarm-to-thrombolysis time.

267 tion of pharmacomechanical catheter-directed thrombolysis to anticoagulation did not result in a lowe

268 MRI in acute stroke treatment (predominantly thrombolysis), to examine the assumptions and theories b

269 approach using anticoagulation, angioplasty/thrombolysis, transjugular intrahepatic portosystemic sh

270 nteraction between SPAN-100 index status and thrombolysis treatment (P < .001) revealing a reduction

271 cal trials but should probably not be denied thrombolysis treatment on the basis of such a profile al

272 teractions between SPAN-100 index status and thrombolysis treatment were observed for the 2 secondary

273 The PEITHO (Pulmonary Embolism Thrombolysis) trial was a randomized (1:1) comparison of

274 used individual patient data from the Stroke Thrombolysis Trialists' (STT) meta-analysis of randomise

275 and those with a contraindication or failed thrombolysis underwent surgery.

276 Patients underwent thrombolysis unless contraindicated, and those with a co

277 hether ultrasound-assisted catheter-directed thrombolysis (USAT) is superior to anticoagulation alone

278 ve stroke management programme would improve thrombolysis use and clinical outcome in patients.

279 We focused on thrombolysis use and outcome in the first full 4 years o

280 er adjuvant intracoronary therapies, such as thrombolysis, vasodilators, glycoprotein IIb/IIIa inhibi

281 thrombolysis, the proportion of golden hour thrombolysis was 6-fold higher after STEMO deployment (6

282 Thrombolysis was associated with a lower risk of recurre

283 intermediate-risk pulmonary embolism trials, thrombolysis was associated with lower mortality (OR, 0.

284 Intravenous thrombolysis was safe in this prospective WUS study of p

285 Thrombolysis was started before transport to hospital if

286 Thrombolysis was started in STEMO if a stroke was confir

287 Older adults were as likely to want stroke thrombolysis when unable to consent (78.1%) as when aske

288 have been devised to capture the benefits of thrombolysis while reducing its risks, but there is limi

289 tion time was a good predictor of successful thrombolysis with a cutoff point of <747 ms having a sen

290 s, thrombectomy was performed in addition to thrombolysis with intravenous alteplase, but benefits we

291 (IST-3) was a randomized controlled trial of thrombolysis with intravenous recombinant tissue plasmin

292 As thrombolysis with recombinant tissue plasminogen activat

293 nset, to endovascular therapy (intraarterial thrombolysis with recombinant tissue plasminogen activat

294 Thrombolysis with streptokinase or alteplase further inc

295 ) trial was a randomized (1:1) comparison of thrombolysis with tenecteplase versus placebo in normote

296 to the current standard of care: intravenous thrombolysis with tissue-type plasminogen activator and

297 Intravenous thrombolysis with tissue-type plasminogen activator rema

298 al ischaemic stroke eligible for intravenous thrombolysis within 4.5 h of onset were recruited from T

299 (chiefly of fatal intracerebral hemorrhage), thrombolysis within 6 h did not affect longer-term survi

300 creases the percentage of patients receiving thrombolysis within the golden hour.